Home > Drugs A – Z > Dimethyl Fumarate (By mouth)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Dimethyl Fumarate (By mouth)

Treats multiple sclerosis (MS).

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Dimethyl fumarate is used to treat the relapsing forms of multiple sclerosis (MS). This medicine will not cure MS, but it may slow some disabling effects and decrease the number of relapses of the disease. This medicine is available only with your doctor's prescription… Read more
Brand names include
Tecfidera
Drug classes About this
Immune Modulator

What works? Research summarized

Evidence reviews

Management of Relapsing-Remitting Multiple Sclerosis [Internet]

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that is more common in women than in men, by a factor of approximately 3:1. Canada has the fifth-highest worldwide prevalence at 240 per 100,000 persons.

Laquinimod, a new oral disease‐modifying drug for multiple sclerosis (MS)

Disease‐modifying therapies (DMTs) for MS currently aim to specifically reduce inflammation in relapsing MS and promote protection and repair of the nervous system in progressive MS. Laquinimod is a new oral disease‐modifying drug (DMD) with dual properties of modulation of the immune system and protection of the nervous system. The authors of this review assessed the efficacy and safety of laquinimod in patients with MS. Concerning the outcomes, they considered relapse, disability progression, inflammatory lesion, and brain atrophy. Among the pertinent literature only one study met the inclusion criteria. The study involved a total of 1106 patients with relapsing‐remitting MS and evaluated the efficacy and safety of laquinimod as unique therapy versus placebo. As far as safety was concerned, common adverse events included headache, back pain, arthralgia, diarrhoea, cough, urinary tract infection, elevated alanine aminotransferase, insomnia, nausea, abdominal pain and sinusitis. The authors were unable to give any clear recommendations for the use of laquinimod as a DMD for MS because the study was poor quality and was funded by a pharmaceutical company. Future studies with higher methodological quality are needed to assess the potential benefits and the safety in a longer period of administration.

The use of the monoclonal antibody rituximab in patients with relapsing remitting multiple sclerosis (RRMS)

This is an update of the Cochrane review "Rituximab for relapsing‐remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).

Summaries for consumers

Laquinimod, a new oral disease‐modifying drug for multiple sclerosis (MS)

Disease‐modifying therapies (DMTs) for MS currently aim to specifically reduce inflammation in relapsing MS and promote protection and repair of the nervous system in progressive MS. Laquinimod is a new oral disease‐modifying drug (DMD) with dual properties of modulation of the immune system and protection of the nervous system. The authors of this review assessed the efficacy and safety of laquinimod in patients with MS. Concerning the outcomes, they considered relapse, disability progression, inflammatory lesion, and brain atrophy. Among the pertinent literature only one study met the inclusion criteria. The study involved a total of 1106 patients with relapsing‐remitting MS and evaluated the efficacy and safety of laquinimod as unique therapy versus placebo. As far as safety was concerned, common adverse events included headache, back pain, arthralgia, diarrhoea, cough, urinary tract infection, elevated alanine aminotransferase, insomnia, nausea, abdominal pain and sinusitis. The authors were unable to give any clear recommendations for the use of laquinimod as a DMD for MS because the study was poor quality and was funded by a pharmaceutical company. Future studies with higher methodological quality are needed to assess the potential benefits and the safety in a longer period of administration.

The use of the monoclonal antibody rituximab in patients with relapsing remitting multiple sclerosis (RRMS)

This is an update of the Cochrane review "Rituximab for relapsing‐remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).

PubMed Health Blog...

read all...